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ABSTRACT
Objective To compare the effect of two different 
automated oxygen control devices on target range (TR) 
time and occurrence of hypoxaemic and hyperoxaemic 
episodes.
Design Randomised cross- over study.
Setting Tertiary level neonatal unit in the Netherlands.
Patients Preterm infants (n=15) born between 24+0 
and 29+6 days of gestation, receiving invasive or 
non- invasive respiratory support with oxygen saturation 
(SpO2) TR of 91%–95%. Median gestational age 26 
weeks and 4 days (IQR 25 weeks 3 days–27 weeks 
6 days) and postnatal age 19 (IQR 17–24) days.
Interventions Inspired oxygen concentration was 
titrated by the OxyGenie controller (SLE6000 ventilator) 
and the CLiO2 controller (AVEA ventilator) for 24 hours 
each, in a random sequence, with the respiratory support 
mode kept constant.
Main outcome measures Time spent within set SpO2 
TR (91%–95% with supplemental oxygen and 91%–
100% without supplemental oxygen).
Results Time spent within the SpO2 TR was higher 
during OxyGenie control (80.2 (72.6–82.4)% vs 68.5 
(56.7–79.3)%, p<0.005). Less time was spent above TR 
while in supplemental oxygen (6.3 (5.1–9.9)% vs 15.9 
(11.5–30.7)%, p<0.005) but more time spent below 
TR during OxyGenie control (14.7 (11.8%–17.2%) vs 
9.3 (8.2–12.6)%, p<0.05). There was no significant 
difference in time with SpO2 <80% (0.5 (0.1–1.0)% vs 
0.2 (0.1–0.4)%, p=0.061). Long- lasting SpO2 deviations 
occurred less frequently during OxyGenie control.
Conclusions The OxyGenie control algorithm was 
more effective in keeping the oxygen saturation within 
TR and preventing hyperoxaemia and equally effective in 
preventing hypoxaemia (SpO2 <80%), although at the 
cost of a small increase in mild hypoxaemia.
Trial registry number NCT03877198
INTRODUCTION
Oxygen therapy for preterm infants with respi-
ratory insufficiency aims to prevent or moderate 
the effects of hypoxaemia on the central nervous 
system, lungs and other organs. Conversely, the 
immaturity of the premature infant’s lungs, eyes 
and antioxidant system renders them vulnerable to 
exposure to supplemental oxygen, and hyperox-
aemia has been linked to the development of bron-
chopulmonary dysplasia (BPD) and retinopathy of 
prematurity (ROP).1 2
Mindful of these morbidities, the inhaled frac-
tion of oxygen (FiO2) is titrated manually, based 
on oxygen saturation (SpO2) readings derived 
from transcutaneous oximetry. Current guidelines 
recommend a lower limit for the SpO2 target range 
(TR) of at least 90% for the preterm infant,3 based 
on the recent NeOProM meta- analysis of individual 
patient data from large randomised controlled 
trials.4 These trials highlighted the potential impact 
of hypoxaemia and hyperoxaemia on preterm 
infants, with the lower TR (85%–89%) associated 
with an increased risk of mortality and necrotising 
enterocolitis and the higher TR (91%–95%) with 
an increased rate of ROP.
While the need to target an SpO2 range is widely 
accepted, data from cohort studies and randomised 
controlled trials point to the difficulty of SpO2 
targeting by manual oxygen titration,5–10 with most 
studies reporting SpO2 values to be within the TR 
less than 50% of the time. Although bedside staff 
adjust the fraction of inspired oxygen (FiO2) rela-
tively frequently to maintain SpO2 within TR, their 
workload limits time availability and makes it diffi-
cult to tailor FiO2 continuously to the infant’s need. 
This is compounded by the neonatal oxygenation 
physiology being unstable and non- linear with 
What is already known on this topic?
 ► Automated oxygen controllers, including the
ones used in this study, increase time spent
within the oxygen saturation target range
compared with manual control.
 ► Hypoxaemia and hyperoxaemia have been
linked to morbidity and mortality in preterm
infants.
What this study adds?
 ► The OxyGenie controller was more effective
in keeping the oxygen saturation within SpO2
target range than the CLiO2 controller.
 ► With OxyGenie, less time was spent above
target range, fewer hypoxaemic and
hyperoxaemic episodes occurred, although with
a small increase in time below target range.
 ► Algorithm design influences how effective SpO2
targeting will be.
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significant time delay between FiO2 adjustment and when SpO2 
reaches a new stable level.11
Given both the importance and difficulty of SpO2 targeting, 
automated oxygen control (AOC) is a logical improvement on 
current practice. In essence, the concept is of an SpO2 input to 
a device holding a set of computational instructions (an algo-
rithm), which then gives an output, an updated value for FiO2. 
Studies comparing automated oxygen titration systems with 
manual titration, conducted over short periods (2–24 hours per 
epoch), have demonstrated an absolute increase in the propor-
tion of time spent with SpO2 within TR varying between 8% and 
31%.12–23 A single study conducted in our institution has exam-
ined the effect of implementation of AOC as standard of care, 
finding a 14% increase in TR time in the postimplementation 
cohort, mostly related to a decrease in time above TR.24
Although several devices offering AOC are now commercially 
available and used in neonatal intensive care units (NICUs), 
comparisons between them are lacking. The NICU of the Leiden 
University Medical Center (LUMC) implemented AOC with the 
CLiO2 algorithm (Vyaire, Yorba Linda, California, USA) with the 
AVEA ventilator as routine care in August 2015. We recently 
replaced the AVEA ventilators with SLE6000 ventilators (SLE 
Limited, South Croydon, UK), which have the VDL 1.1 algo-
rithm for AOC embedded as the “OxyGenie” option.17 25 This 
provided the unique setting where caregivers were competent to 
work with both ventilators, thus making feasible a safe compar-
ison between the two oxygen controllers.
Based on described differences in the function of algorithms 
developed for AOC, it is likely that they will exhibit differences in 
performance.17 25 We recently observed that the CLiO2 algorithm 
was effective mostly in decreasing time above TR,24 whereas the 
first clinical study using OxyGenie reported a decrease in both 
time under and above TR and a virtual elimination of longer 
episodes outside the TR.23 We therefore hypothesised that the 
OxyGenie may be more effective than CLiO2 in maintaining 




We performed a randomised crossover trial in the NICU of 
the LUMC, a tertiary level neonatal unit with 25 NICU beds 
and 850 intensive care admissions per year. The Dutch Central 
Committee on Research Involving Human Subjects approved the 
study. Written informed parental consent was acquired prior to 
participation of each infant in the study.
Study population
Preterm infants born between from 24 weeks and up to and 
including 29 weeks of gestation who were receiving invasive 
mechanical ventilation or non- invasive respiratory support were 
assessed for eligibility . Initially, infants were considered eligible 
if they required supplemental oxygen with an FiO2 ≥0.25 at the 
time of enrolment and for at least 18 hours of the preceding 
24 hours, but as the study progressed an alternative FiO2 eligi-
bility criterion was added (FiO2 coefficient of variation ≥0.1 in 
the preceding 24 hours) to improve recruitment rate. Infants 
were excluded in case of major congenital anomalies or acute 
instability.
Automated oxygen control algorithms
The CLiO2 algorithm embedded in the AVEA ventilator is a 
hybrid rule- based adaptive controller. It makes initial FiO2 
adjustments that are proportional to the difference between 
the measured SpO2 and the limits of the SpO2 TR. Subsequent 
adjustments also take into account this difference, as well as the 
SpO2 trend and basal oxygen requirement, the baseFiO2. The 
baseFiO2 is periodically updated by interrogation of 5 min of 
recent SpO2 and FiO2 data where specific conditions are met, 
averaged along with the current baseFiO2 value.
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The OxyGenie algorithm embedded in the SLE6000 ventilator 
is an adaptive proportional- integral- derivative (PID) controller. 
The P, I and D terms each have separate coefficients, and in each 
case are adjusted from raw values to better suit the physiology 
of a neonate and account for the limitations of pulse oximetry. 
The basal FiO2, referred to as Reference FiO2, is calculated every 
30 min using 60 min of preceding FiO2 and SpO2 values.
Study procedures
A crossover design was used to study each infant on the same 
respiratory support mode. Infants received two consecutive 
study periods of 24 hours each, one with oxygen therapy under 
the control of the CLiO2 algorithm and the other with the 
OxyGenie algorithm, in random sequence. Web- based randomis-
ation by Castor EDC (Castor, Amsterdam, The Netherlands) was 
used, stratified by mode of respiratory support (invasive or non- 
invasive) using variable (4, 6) block sizes. After the first study 
period, the alternative ventilator was substituted, and a washout 
period of 1 hour was applied before data recording restarted to 
prevent a carryover bias. The study was completed when AOC 
with each device had been applied for 24 hours, with standard 
respiratory management thereafter resuming. The SpO2 TR for 
both study periods was 91%–95%.
No other extra interventions were given. Infants did receive 
all standard treatments, and ventilation settings were at the 
discretion of the caregiver.
Data collection and analysis
Baseline characteristics were noted for each infant, including 
details on respiratory support and clinical state. The primary 
outcome was the proportion of time spent within the SpO2 TR 
(91%–95% with supplemental oxygen or 91%–100% without 
supplemental oxygen). SpO2 and intended FiO2 values were 
recorded each second from the data port or display of the 
ventilator under investigation. Secondary outcomes included: 
proportion of time in various degrees of hypoxaemia (SpO2 
<80%, SpO2 80%–84%, SpO2 85%–90%, SpO2  ≤90%)  and 
hyperoxaemia (SpO2 >95%, SpO2 96%–98% and SpO2 >98% 
while receiving supplemental oxygen); SpO2 and FiO2 coefficient 
of variation; frequency of 30 and 60 s episodes in hypoxaemia 
and hyperoxaemia; bradycardic episodes (heart rate <100 beats 
per  minute  for  ≥10  consecutive  seconds);  frequency  of  FiO2 
adjustments, both manual and automatic and average oxygen 
exposure.
Continuous data are represented as median (IQR) or mean±SD 
as appropriate, with standard tests for normality. Time within 
particular SpO2 ranges was collated for each infant individually 
and expressed as proportion of usable recorded time. Differ-
ences in time in TR and other outcomes were assessed with the 
Wilcoxon matched- pairs test. The intention- to- treat principle 
was applied. Statistical analyses were performed by an analysist 
blinded to allocation using R V.3.4.4 (R Core Team (2016). R: 
A language and environment for statistical computing, R Foun-
dation for Statistical Computing, Vienna, Austria, URL: https://
www. R- project. org/).
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Sample size calculation was based around data from previous 
studies of the two automated control algorithms. In a study 
using the CLiO2 in Leiden in preterm infants the proportion of 
time in the SpO2 TR was 60.4% (±15.6%).
24 In the first clinical
study of the OxyGenie algorithm TR time was 78% (±15%). 
We considered a difference of 5% TR time a clinically relevant 
difference. For a two- sided paired statistical test, 44 infants 
would be needed assuming a SD of 10% for a power of 90% 
and an alpha of 0.05. Because a non- parametric test would be 
used in the analysis, we made a 15% addition to the sample size, 
as described by Lehmann,27 requiring a total of 50 participants.
Early termination
Just prior to study commencement, the SLE6000 ventilator was 
deployed as the standard device for neonatal respiratory support 
at LUMC. The AVEA ventilators were thereafter only used when 
an infant was included in the study. Based on historical data, we 
anticipated to complete recruitment in a year, which was also 
considered the maximum time competence of medical staff in 
working with both ventilators could be guaranteed. However, 
the recruitment rate was slower than expected and to ensure 
patient safety and an unbiased comparison of both oxygen 
control with the two ventilators the trial was terminated after a 
12- month recruiting period.
RESULTS
The study ran from February 2019 to February 2020, during 
which consent was sought from 27 parent couples of which 15 
agreed to participate (figure 1). All participating infants (n=15, 
baseline characteristics table 1) completed the crossover compar-
ison. In one infant, the second study period (OxyGenie control) 
was halted after 18 hours to allow treating clinicians to switch 
from continuous positive airway pressure to nasal high flow in 
response to nasal pressure areas. All study periods were included 
in the analysis. The total duration of recordings was 23 hours 
and 19 min (22:52–23:30) during OxyGenie control and 23 
hours and 51 min (23:49–23:56) with the CLiO2 controller. A 
total of 2.9% (2.1%–5.0%) and 0.3% (0.2%–0.6%) of the time 
the SpO2 signal was missing, respectively.
Histograms of pooled SpO2 data from the two automated 
control periods are shown in figure 2, demonstrating a narrower 
SpO2 distribution and a lower median SpO2 during OxyGenie 
control resulting in a higher proportion of time within the SpO2 
TR. On per patient analysis, for the study primary outcome, 
there was a 11.7% increase in time within the SpO2 TR during 
oxygen control with the OxyGenie algorithm when compared 
with the CLiO2 device (table 2). Twelve infants spent more time 
in TR with OxyGenie control and three with CLiO2 control 
(figure 3). During the OxyGenie period, less time was spent 
above the TR while in supplemental oxygen, but more time 
spent below TR. SpO2 values <80% were very infrequent 
throughout the study, and the time with SpO2 <80% did not 
differ between control devices. The coefficient of variation for 
SpO2 was similar for both devices (3.3% (2.6%–4.0%) vs 3.2% 
(3.0%–3.4%), p=0.82).
Figure 1 CONSORT flow diagram.
Table 1 Baseline characteristics
Characteristic
n=15 Definition Statistics Results
Gestational age weeks, days Median (IQR) 26.4 (25.3–27.6)
Birth weight g Median (IQR) 945 (740–1120)
Postnatal age days Median (IQR) 19 (17–24)
Gender Female/male n 4/11
Ventilation mode Invasive 
ventilation/CPAP
n 2/13
Average FiO2 over 24 
hours prestudy
Fraction Median (IQR) 0.26 (0.24–0.29)




CPAP, continuous positive airway pressure; FiO2, fraction of inspired oxygen.
Figure 2 SpO2 histograms. Pooled time spent per SpO2 value as 
proportion of total usable time, while receiving supplemental oxygen 
and ambient air (total) or while only receiving supplemental oxygen. 
Dashed lines represent the limits of the SpO2 target range.
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There was a decrease in frequency of both hypoxaemic and 
hyperoxaemic episodes during OxyGenie control (table 3). 
Bradycardic episodes  (<100 bpm for ≥10 s) were  rare  in both 
epochs and were not different (0.3 (0.1–0.6) vs 0.2 (0.0–0.5) per 
hour, p=0.22).
OxyGenie adjusted FiO2 about 10 times more frequently 
than the CLiO2 device (1155 (1044–1255) vs 194 (178–205) 
adjustments/hour, p=0.001). The average delivered FiO2 
was  similar  during  both  study  periods  (0.27+−0.05  vs  0.26 
+−0.08, p=0.56). FiO2 was more variable when titrated by the 
OxyGenie algorithm (coefficient of variation 19.5% (15.2%–
25.0%) vs 13.3% (12.8%–19.0%), p=0.015). During OxyGenie 
control, manual overrides of the AOC were made only in one 
individual subject (four adjustments) versus nine individuals (16 
adjustments) with manual overrides during the period of CLiO2 
oxygen control.
DISCUSSION
In this randomised controlled crossover study, automated titra-
tion of inspired oxygen concentration using the OxyGenie 
controller significantly increased the time spent within the SpO2 
TR when compared with the CLiO2 controller. The difference 
in controller function was reflected in the SpO2 histogram, 
with a more balanced distribution of SpO2 values within and 
around the TR during OxyGenie control. This resulted in 
significantly less time spent above the TR, and fewer hyperox-
aemic episodes, although at the cost of a small increase in time 
spent with SpO2 values below TR. The greater time with SpO2 
in the range 80%–90% with OxyGenie compared with CLiO2 
control was not accompanied by an increase in the frequency of 
hypoxic episodes, which were, indeed, significantly fewer during 
OxyGenie control. These results suggest that algorithm design, 
and in particular algorithm responsiveness, plays an important 
role in how successful SpO2 targeting will be with a given oxygen 
control device.
This is the first study to compare two different ventilators 
incorporating AOC algorithms head- to- head. Although earlier 
studies have individually compared the algorithms in question 
to manual oxygen titration,15–20 23 24 heterogeneity between the 
studies has precluded drawing inferences about their function 
relative to each other. Our findings in relation to proportion of 
time within TR were similar to previous studies, implying that 
the SpO2 targeting results achieved by controllers in our study 
were representative of their overall performance. Compared 
with the TR time of 80% in this study, other studies of OxyGenie 
control have demonstrated TR times of 81%23 and 88%.28 For 
CLiO2 (69% TR time in this study), other studies have shown TR 
time of 40%,15 58%,16 62%,18 76%,19 73%20 and 62%24).
The study was terminated before reaching the predetermined 
sample size of 50 infants. The deployment of the SLE6000 venti-
lator at LUMC had an impact on numbers of eligible infants by 
virtue of (1) the option of nasal high flow (not available with 
the AVEA ventilator) being taken up at an early juncture in 
many preterm infants, precluding involvement in the study and 
(2) fewer infants spending >18 of the preceding 24 hours with
an FiO2 ≥0.25, in part attributable to the progressive approach
to weaning FiO2 inherent in OxyGenie control. As a result, the
recruitment rate was lower than expected. To prevent a loss of
competence in handling the AVEA ventilator, potentially intro-
ducing a bias into the study, we decided to terminate the study
prematurely. Truncated clinical studies can lead to overexagger-
ated observed effects.29 30 For our study, this would mean that
the observed benefit for the OxyGenie controller in comparison
Table 2 Proportions of time within SpO2 ranges
Oxygenie CLiO2 P value*
Time SpO2 within 
target range†
80.2 (72.6–82.4)% 68.5 (56.7–79.3)% 0.005
Time SpO2 below 
target range
14.7 (11.8–17.2)% 9.3 (8.2–12.6)% 0.020
Time SpO2 above 
target range‡
6.3 (5.1–9.9)% 15.9 (11.5–30.7)% 0.001
SpO2 85%–90% 12.6 (10.9–13.1)% 8.5 (7.6–11.0)% 0.020
SpO2 80%–84% 1.2 (0.7–3.0)% 0.8 (0.5–0.9)% 0.003
SpO2 <80% 0.5 (0.1–1.0)% 0.2 (0.1–0.4)% 0.061
SpO2 96%–98% while 
FiO2≥0.22
6.1 (5.0–9.5)% 15.5 (10.9–27.4)% 0.001
SpO2 >98% while 
FiO2≥0.22
0.2 (0.1–0.4)% 1.4 (0.4–3.7)% 0.001
Data in median (IQR)
*Wilcoxon matched pairs test.
†91% ≤SpO2 ≤95% or SpO2 ≥96% while FiO2=0.21.
‡SpO2 ≥96% while FiO2 ≥0.22.
Figure 3 Comparison of OxyGenie control with CLiO2 control. 
Individual paired values of proportion of time within TR while on 
OxyGenie control and while on CLiO2 control. Horizontal bar=median. 
Within TR=91%–95% with supplemental oxygen or 91%–100% 
without supplemental oxygen. TR, target range.
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to CLiO2 controller may overestimate the true benefit. However, 
if we had planned for an interim analysis to decide for stop-
ping the trial after 15 patients, we would have surpassed both 
the Pocock and O'Brien- Fleming boundary criteria for clearly 
showing evidence of benefit for the OxyGenie controller. For 
a single interim analysis, Pocock recommends a p- threshold of 
0.029431 and O'Brien- Fleming recommends a more conservative 
0.0054 p- threshold32 to control for type I error due to repeated 
testing. The apparent benefit of OxyGenie is also demonstrated 
by a 11.7% improvement which is more than twice the clini-
cally relevant difference of 5% for which the current study was 
powered.
There was an imbalance between the two oxygen control 
devices in the proportion of missing values. Both algorithms 
use a built- in Masimo pulse oximeter with similar algorithms 
making it unlikely that the actual reliability of pulse oximeter 
measurement was different between ventilators. But, to ensure 
a prompt response to TR deviations, OxyGenie uses a 2–4 s 
averaging time whereas CLiO2 uses an 8 s averaging time. This 
could lead to more missing signal, as shorter averaging times 
are inherently more susceptible to disturbances. Furthermore, 
although the same SET technology is used, manufacturers are 
free to choose the signal quality threshold below which SpO2 is 
reported as missing. It seems likely that the handling of the SpO2 
signal within the SLE6000 is more conservative in this respect. 
Because the proportion of missing signal was still relatively low 
in both oxygen control periods, its effect on the outcomes of this 
study is likely to have been modest.
This study compared two ventilators rather than purely the 
AOC algorithms. It is possible that ventilator mechanics also 
played a role in the effectiveness of oxygen control as well as 
other aspects of ventilator function including the circuit flow 
characteristics.33 However, this was a pragmatic choice as license 
agreements precluded us from implementing two algorithms in 
one ventilator.
Contrary to our hypothesis, the benefit of an increase in SpO2 
TR time with OxyGenie control was gained with a lesser occur-
rence of hyperoxaemia, at the cost of a minor increase in time 
spent with SpO2 80%–90%. Although at first glance it appears 
there is a trade- off between hyperoxaemia and hypoxaemia, 
the reduction in hypoxaemic episodes with OxyGenie control 
suggests that hypoxaemia is resolved more quickly. This is in 
line with the clinical observation of caregivers, who reported 
that OxyGenie responded more rapidly to SpO2 deviations into 
hypoxaemia than CLiO2. Compared with other studies, time 
with SpO2 <80% was modest with both controllers. For the 
OxyGenie controller, it was 0.5% in our study vs 0%23 previ-
ously; for the CLiO2 controller, it was 0.2% whereas other 
studies reported 9.8%,15 1.2% and 0.8%,18 3.1%,19 1.3%20 and 
0.9%.24
The increase in time spent under TR could be due to a lower 
median SpO2 during OxyGenie control (93% vs 94%) on the 
steeper part of the oxygen- dissociation curve. The higher median 
SpO2 during CLiO2 control could be because, according to the 
patent, an SpO2 of 94% is targeted while in TR and the FiO2 is 
rarely titrated below the BaseFiO2.
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Even though the benefit of AOC on SpO2 TR time is well- 
established, the effect on clinical outcome is still unknown. 
The effect of SpO2 targeting within different ranges on clinical 
outcome was demonstrated by the NeOPRoM trials,4 and a range 
of studies have evidenced the harmful effects of hypoxaemia and 
hyperoxaemia (and episodes thereof),34–39 both of which are 
affected by AOC. We would maintain that when searching for 
clinical effect of AOC, it is important to use an algorithm that 
most successfully avoids and mitigates SpO2 deviations, because 
the effect on clinical outcomes may be modest and in some cases 
may be difficult to detect given their relatively low incidence.
Finally, low compliance in TR adherence such as reported in 
the NeOPRoM trials4 could be improved on by using AOC. For 
the best differentiation between treatment groups, it is important 
to have a controller that best targets the predefined ranges.
CONCLUSION
In this study, the OxyGenie controller was more effective in 
keeping the oxygen saturation within TR and preventing hyper-
oxaemia, and just as effective in preventing hypoxaemia (SpO2 
<80%), although at the cost of a small increase with SpO2 
80%–90%.
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